A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain
Phase: PHASE2
Conditions: Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Sponsor: Eliem Therapeutics (UK) Ltd.

Synopsis ETX-018810-202 
 
ETX-018810 
 
 
Eliem Therapeutics (UK) Ltd 
 
Confidential 
Page 1 of 7 
Version 1.0, 07 July 2020 
 
 
 
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to 
Evaluate the Efficacy and Safety of ETX-018810 in Subjects with Diabetic Peripheral 
Neuropathic Pain 
 
NCT Number: 04688671 
 
Document Date: 7th July 2020 
 
 
 

Synopsis ETX-018810-202 
 
ETX-018810 
 
 
Eliem Therapeutics (UK) Ltd 
 
Confidential 
Page 7 of 7 
Version 1.0, 07 July 2020 
 
The treatment comparison for the change from baseline at Week 4 was estimated using a Mixed 
Model Repeated Measures (MMRM), which included the baseline score as a covariate; treatment 
group, visit (week), and the treatment-by-visit (week) as fixed effects; and a repeated structure 
that acknowledged the visits within a subject using an unstructured covariance structure. The 
Kenward-Rogers (1997) approximation was used to estimate the denominator degrees of 
freedom. The estimate, standard error, 90% CI, and associated p-value (2-sided) were presented.